ALXN1720

COMBINATION_PRODUCT2 trials

Sponsors

Alexion Pharmaceuticals, Inc.

Conditions

Generalized Myasthenia GravisProteinuria

Phase 1

Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria

CompletedNCT05314231

Alexion Pharmaceuticals, Inc.Proteinuria

Start: 2022-06-29End: 2023-05-31Updated: 2023-06-29

Phase 3

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

Active, not recruitingNCT05556096

Alexion Pharmaceuticals, Inc.Generalized Myasthenia Gravis

Start: 2022-11-21End: 2027-08-31Updated: 2026-06-17

Related Papers

Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis

JAMA Neurology2026-07-271 citations

Study design and methodology of the PREVAIL trial: a phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of subcutaneous ALXN1720 in adults with generalized myasthenia gravis (P1-5.008)

Neurology2023-04-251 citations